Fisher And Paykel Healthcare Stock Faces Fresh US Tariff Pressure

The US decision to lift tariffs on New Zealand exports from 10% to 12.5% puts a direct question mark over some of the country’s most US dependent exporters. For investors, this is less about headline politics and more about how higher border taxes could squeeze margins, shift supply chains, or alter demand for specific stocks. This article looks at three stocks from the New Zealand Exporters With Direct US Tariff Exposure screener that appear particularly vulnerable to the new tariff regime, and explains what the news could mean for their earnings risk, pricing power, and overall investment appeal.

Sanford (NZSE:SAN)

Overview: Sanford is a New Zealand seafood company that farms, catches, processes and sells a wide range of fish, mussels and salmon to customers around the world, including North America, Asia and Europe. It operates through wildcatch and aquaculture, supplying species from hoki and orange roughy to king salmon and greenshell mussels into retail, foodservice and industrial channels.

Operations: Sanford generates about NZ$568.3m in revenue from farming, harvesting, processing and selling seafood products, with key markets including New Zealand (NZ$218.1m), North America (NZ$98.7m), Europe (NZ$86.2m) and China (NZ$64.8m).

Market Cap: NZ$652.7m

Investors looking at Sanford now have to weigh apparently cheap valuation metrics and stronger recent margins against a tariff shock that directly targets one of its largest offshore markets. North American customers currently account for close to NZ$100m of revenue, so a move from 10% to 12.5% US tariffs risks compressing already modest forecast returns and forcing either price hikes or thinner margins. Earnings have been improving and the company has a long operating history, but reliance on external borrowing, mixed board independence and forecasts that point to flat earnings alongside only modest revenue growth leave little room for error if demand softens or currency moves in an unfavourable direction.

Sanford’s margins and tariffs may be getting all the attention, but the real story could be buried in the balance sheet and cash flows, and the Sanford financial health report could reveal pressures most investors are glossing over, especially if US demand does not fully absorb higher costs Sanford financial health report

Fonterra Co-operative Group (NZSE:FCG)

Overview: Fonterra Co-operative Group is New Zealand’s largest dairy exporter, collecting milk from farmer shareholders and turning it into powders, cheese, butter, yoghurt and other dairy products sold to food manufacturers, retailers and foodservice customers worldwide under brands such as Anchor, Mainland and Anmum.

Operations: Fonterra generates about NZ$21.6b in revenue from its core operations, partly offset by eliminations and segment adjustments in group reporting.

Market Cap: NZ$10.2b

Fonterra Co-operative Group may look appealing, with a low P/E, a share price well below an estimated cash flow value and a high 8.98% dividend yield. However, the new 12.5% US tariff squarely hits one of its key export markets where margins already look thin. Net profit margins sit at 4.2%, down from 4.8%, and return on equity is only 11.9%, which limits the cushion to absorb higher border taxes without further pressure on earnings. High reliance on external borrowing and a dividend that is not well covered by earnings point to funding and payout risk if export pricing comes under more strain. With tariff uncertainty and limited visibility on future growth, investors face more questions than answers around how resilient this co operative really is.

An 8.98% yield, thin 4.2% margins and heavier US tariffs could be masking where Fonterra Co-operative Group’s real pressure point sits, and the full story may only emerge in the 2 key rewards and 2 important warning signs

Fisher & Paykel Healthcare (NZSE:FPH)

Overview: Fisher & Paykel Healthcare designs and sells respiratory care and sleep apnea devices used in hospitals and homes worldwide, from high flow oxygen systems for intensive care units to masks and humidifiers for chronic conditions.

Operations: Fisher & Paykel Healthcare generates about NZ$2.3b in revenue from respiratory products, with roughly NZ$1.1b from North America, NZ$620.1m from Europe, NZ$476.1m from Asia Pacific and NZ$106.1m from other regions.

Market Cap: NZ$23.5b

Fisher & Paykel Healthcare is presented as a high quality respiratory equipment company, with a 20.3% net margin, 22.1% ROE and growing hospital and homecare demand. However, the set up is less comfortable when viewed alongside its rich P/E, stretched versus some valuation estimates, and the growing tariff burden on New Zealand made hospital products. The new 12.5% US tariff lands on top of existing duties that management already flags as a drag on margins. Mexico based manufacturing or pricing moves may not fully offset the squeeze if US buyers push back on higher costs. Earnings growth forecasts and recurring consumables revenue are appealing, yet the stock already trades above some fair value estimates, so any hit to US competitiveness or slower clinical adoption could leave late arriving investors with more downside than upside priced in.

Fisher & Paykel Healthcare’s rich P/E and tariff hit on New Zealand made hospital gear could be masking where the real tension sits, and the analyst forecasts for Fisher & Paykel Healthcare may quietly show how expectations and execution are starting to drift.

Take Control of Your Investment Journey

If Sanford or any of these companies are making you feel more cautious, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Alternatives Before Momentum Flies Past

Fresh ideas move fast, and the best breakout opportunities are often identified by early movers while the data still matters and prices have not fully adjusted, so timing can be important.

• Target resilient income by scanning a curated pool of companies in the 472 dividend fortresses that aim to keep cash flows and balance sheets front and center.
• Spot potential early leaders in future computing by checking the hand picked 26 quantum computing stocks positioned around real commercial projects rather than distant promises.
• Follow the trend in automation by reviewing the carefully filtered 33 robotics and automation stocks before momentum buyers arrive and push weaker candidates into the mix.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com